Clinical Trial Update: A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating KYN-5356 for cognitive impairment associated with schizophrenia is currently recruiting. Sponsor: Kynexis B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment Associated with Schizophrenia

Drugs mentioned

• KYN-5356 (KYN-5356)

Snippet

Sponsor: Kynexis B.V. | Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS) | Phase 2 | Status: RECRUITING